<?xml version="1.0" encoding="UTF-8"?>
<p>Another serious problem posed by the COVID-19 pandemic is the treatment continuity of TB patients. The nature of the disease, with extended treatment regimens and poor outcomes with drug resistance resulting from therapy discontinuation, are significant problems even in regular times, all the more in a pandemic context with numerous and stringent isolation measures [
 <xref rid="B40" ref-type="bibr">40</xref>]. This shifts the directly observed therapy to self-administered therapy, for which digital-health technologies such as electronic medication monitors and video-supported therapy were recommended to ensure adherence to treatments [
 <xref rid="B41" ref-type="bibr">41</xref>]. Discontinuation risks and other challenges faced by the tuberculosis clinical trials in the face of COVID-19 have been discussed, sounding the alarm around these threats [
 <xref rid="B42" ref-type="bibr">42</xref>].
</p>
